Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
BRIEF-United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing Oct 14 (Reuters) - United Therapeutics Corporation UTHR.O:
UNITED THERAPEUTICS CORP - ENTERS SETTLEMENT AGREEMENT WITH LIQUIDIA TO RESOLVE LITIGATION - SEC FILING
UNITED THERAPEUTICS CORP - LIQUIDIA TO PAY UNITED THERAPEUTICS $330.40 MILLION UNDER SETTLEMENT AGREEMENT - SEC FILING
UNITED THERAPEUTICS CORP - PARTIES TO SEEK DISMISSAL OF LITIGATION WITHIN TEN DAYS AFTER $185 MILLION PAYMENT - SEC FILING
UNITED THERAPEUTICS CORP - LIQUIDIA TO CEASE SALES OF YUTREPIA WITH PH-ILD INDICATION UPON FDA APPROVAL - SEC FILING
UNITED THERAPEUTICS CORP - LIQUIDIA TO MARKET YUTREPIA ONLY TO PRACTITIONERS TREATING PAH - SEC FILING
UNITED THERAPEUTICS CORP - LIQUIDIA TO TERMINATE ASCENT TRIAL COHORTS STUDYING PH-ILD AND CEASE DATA PUBLICATION - SEC FILING
Source text: [ID:n0001104659-26-115723]
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug